A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This is a Phase 3 randomized, double blind, placebo controlled study of tasquinimod in asymptomatic to mildly symptomatic patients with metastatic CRPC to confirm the effect of tasquinimod on delaying disease progression compared with placebo. Approximately 1200 eligible patients with metastatic CRPC will be randomly assigned in a 2:1 ratio to 1 of 2 treatment groups: Treatment Group A (tasquinimod 0.25, 0.5, or 1 mg/day; n=800) or Treatment Group B (placebo; n=400).
Epistemonikos ID: 2eb6406d6b712348c47232a3243374951385d29b
First added on: May 06, 2024